Clinical correlations between chronic hepatitis C infection and decreasing bone mass density after treatment with interferon-alpha

Vahid Babaei, Masoud Ghorbani, Nastaran Mohseni, Hojjat Afraid, Yassaman Saghaei, Shahram Teimourian
  • Asian Pacific Journal of Tropical Biomedicine, February 2017, Elsevier
  • DOI: 10.1016/j.apjtb.2016.11.027

Correlations between chronic HCV infection and bone mass density after treatment with IFN-alpha

What is it about?

To compare the bone mass density in chronic hepatitis patients before and after interferon-α treatment.

Why is it important?

Due to the lack of published information about the effects of IFN-α treatment on quality of life in patients with chronic HCV in Iran, it was important to study the impact of IFN-α on quality of life in patients with chronic HCV and investigate the occurrence of clinical factors associated with IFN-α therapy that induces major depression in patients.

Perspectives

Dr Masoud Ghorbani (Author)
Pasteur Institute of Iran

Chronic hepatitis C virus infection did increase the risk of development of metabolic bone disease in this cohort. Indeed, greater reduction of bone mass density occurs in advanced liver fibrosis. The bone loss in earlier stages of chronic hepatitis C infection is likely to result from increased bone reduction rather than decreased bone formation. Overall, these observations suggest an important role for chronic hepatitis C virus infection in increased bone turnover in osteodystrophy pathogenesis

The following have contributed to this page: Dr Masoud Ghorbani and Dr Masoud Ghorbani